Participant flow

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105). · Source last updated 2026-05-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received Sotorasib 960 mg PO QD until there was evidence of disease progression, intolerance to study medication, or withdrawal of consent.

   id

   FG000

   title

   Sotorasib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Participants continuing study

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         12

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         6

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         6

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Administration of sotorasib orally (PO) once daily (QD) was permitted to continue until there was evidence of disease progression, intolerance to study medication, or withdrawal of consent. The primary analysis occurred after all participants enrolled had the opportunity to complete 6 months on study or withdrew from study.

recruitment Details

A total of 12 participants were enrolled in the study in Hong Kong and Taiwan. The study is currently ongoing; results are reported up to the primary data cut-off date of 31 December 2021.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice